[1] Giuliani E,As-Sanie S,Marsh EE.Epidemiology and management of uterine fibroids[J]. Int J Gynaecol Obstet,2020,149(1):3-9. [2] Stewart EA,Cookson CL,Gandolfo RA,et al.Epidemiology of uterine fibroids:A systematic review[J]. BJOG,2017,124(10):1501-1512. [3] Marsh EE,Al-Hendy A,Kappus D,et al.Burden,prevalence,and treatment of uterine fibroids:A survey of U.S. women[J]. J Womens Health (Larchmt),2018,27(11):1359-1367. [4] Pavone D,Clemenza S,Sorbi F,et al.Epidemiology and risk factors of uterine fibroids[J]. Best Pract Res Clin Obstet Gynaecol,2018,46:3-11. [5] Chantasartrassamee P,Kongsawatvorakul C,Rermluk N,et al.Preoperative clinical characteristics between uterine sarcoma and leiomyoma in patients with uterine mass,a case-control study[J]. Eur J Obstet Gynecol Reprod Biol,2022,270:176-180. [6] Travaglino A,Raffone A,Santoro A,et al.Risk of recurrence in uterine leiomyoma with bizarre nuclei:A systematic review and meta-analysis[J]. Geburtshilfe Frauenheilkd,2021,81(11):1217-1223. [7] Ming X,Zhou J,Gou J,et al.A prognostic index model for predicting long-term recurrence of uterine leiomyoma after myomectomy[J]. PLoS One,2021,16(7):e0254142. [8] 杨海生,赵培培,李昱橦. 子宫肌瘤剔除术后残留复发的相关影响因素研究[J]. 实用癌症杂志,2022,37(12):2074-2076. [9] 谢幸,孔北华,段涛. 妇产科学[M]. 9版. 北京:人民卫生出版社,2018:303. [10] 子宫肌瘤的诊治中国专家共识专家组. 子宫肌瘤的诊治中国专家共识[J]. 中华妇产科杂志,2017,52(12):793-800. [11] 汪雯雯,王世宣. 子宫肌瘤诊治相关指南解读[J]. 实用妇产科杂志,2022,38(2):101-103. [12] 任常,冯力民,段华,等. 2021国际妇科内镜学会宫腔镜子宫肌瘤切除术指南解读[J].中华妇产科杂志,2022,57(11):880-885. [13] 杨建宏,严海燕. 子宫肌瘤剔除术后肌瘤复发相关危险因素的影响分析[J]. 实用妇科内分泌电子杂志,2022,9(13):36-38. [14] Kotani Y,Tobiume T,Fujishima R,et al.Recurrence of uterine myoma after myomectomy:Open myomectomy versus laparoscopic myomectomy[J]. J Obstet Gynaecol Res,2018,44(2):298-302. [15] 王运萍,徐佳,张潍,等. 子宫肌瘤剔除术后复发的影响因素及促性腺激素释放素激动剂的预防效果[J]. 中国肿瘤临床与康复,2019,26(8):929-932. [16] Akhter S,Jahan K,Afrose R,et al.Risk association,clinical presentation and management of uterine leiomyoma[J]. Mymensingh Med J,2021,30(4):907-912. [17] 许娜,谭丽丽,刘欣欣,等. 北京地区育龄女性子宫肌瘤流行特征及发病影响因素研究[J]. 华南预防医学,2022,48(8):999-1002. [18] Lewis TD,Malik M,Britten J,et al.A Comprehensive review of the pharmacologic management of uterine leiomyoma[J]. Biomed Res Int,2018,2018:2414609. [19] Tyan P,Amdur R,Berrigan M,et al.Differences in postoperative morbidity among obese patients undergoing abdominal versus laparoscopic hysterectomy for benign indications[J]. J Minim Invasive Gynecol,2020,27(2):464-472. |